SCHEMBL293067

SCHEMBL293067

O=C(OC/C=C/c1ccccc1)OC/C=C/c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.57
PAM P19021 1/20 0.57
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56
MMP12 P39900 1/20 0.56
CACNA1B Q00975 2/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
RECQL P46063 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 2/20 0.47
MAOB P27338 1/20 0.47
NPC1 O15118 2/20 0.47
HDAC3 O15379 1/20 0.47
TNKS O95271 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HCAR2 Q8TDS4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3292040 0.91 MEN1 (0.51) IDO1PAMMMP1MMP2MMP9
SCHEMBL3292037 0.91 MEN1 (0.51) IDO1PAMMMP1MMP2MMP9
SCHEMBL28425115 0.91 MMP1 (0.52) IDO1PAMMMP1MMP2MMP9
SCHEMBL6649727 0.90 LMNA (0.59) IDO1PAMMMP1MMP2MMP9
SCHEMBL6823668 0.90 LMNA (0.59) IDO1PAMMMP1MMP2MMP9
SCHEMBL1158019 0.89 MMP1 (0.51) IDO1PAMMMP1MMP2MMP9
SCHEMBL1158016 0.89 MMP1 (0.51) IDO1PAMMMP1MMP2MMP9
SCHEMBL13923795 0.89 MMP1 (0.51) IDO1PAMMMP1MMP2MMP9
SCHEMBL293068 0.88 IDO1 (0.57) IDO1PAMMMP1MMP2MMP9
SCHEMBL3324115 0.88 IDO1 (0.57) IDO1PAMMMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116265438-B Synthesis method of 5-HT6 receptor molecule based on C-N-axis indole olefin axial chirality 南京理工大学 2024-10-29 CN claimed
CN-116265438-A Synthesis method of 5-HT6 receptor molecule based on C-N-axis indole olefin axial chirality 南京理工大学 2023-06-20 CN claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
EP-4676937-A1 METHODS OF SYNTHESIZING FLUORINATED MACROCYCLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-14 EP disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 US disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 WO disclosed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 WO disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 US disclosed
CN-116265438-B Synthesis method of 5-HT6 receptor molecule based on C-N-axis indole olefin axial chirality 南京理工大学 2024-10-29 CN disclosed
EP-0941104-A4 PEPTIDE SYNTHESIS WITH SULFONYL PROTECTING GROUPS UNIV CALIFORNIA (US) 2002-01-02 EP disclosed
US-6130349-A USING COMPLEX OF MOLYBDENUM, TUNGSTEN OR CHROMIUM WITH 1,1*-BINAPHTHYL SYSTEM CONTAINING HETEROCYCLIC NITROGEN GROUP; ENANTIO- AND REGIOSELECTIVITY THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2000-10-10 US disclosed
WO-1999032225-A9 CATALYTIC COMPOSITION BASED ON CHIRAL LIGANDS WITH MOLYBDENUM, TUNGSTEN OR CHROMIUM AND METHOD FOR ASYMMETRIC ALKYLATION OF ALLYLIC SUBSTRATES UNIV LELAND STANFORD JUNIOR (US) 1999-09-30 WO disclosed
EP-0941104-A1 PEPTIDE SYNTHESIS WITH SULFONYL PROTECTING GROUPS The Regents of the University of California (US) 1999-09-15 EP disclosed
US-5859191-A TREATING FREE TERMINAL ALPHA AMINE WITH ACTIVATING AGENT PRODUCING AMIDE WHICH IS DEPROTONATED WITH A BASE AND MODIFIED WITH AN ELECTROPHILE, THAN CLEAVING USING A NUCLEOPHILIC SUBSTUTION REACTION TO PROVIDE SECONDARY AMINE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-01-12 US disclosed
WO-1998024461-A1 PEPTIDE SYNTHESIS WITH SULFONYL PROTECTING GROUPS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-06-11 WO disclosed
US-4851440-A ASTHMA HOECHST AKTIENGESELLSCHAFT (DE) 1989-07-25 US disclosed
EP-0260923-A2 Temperature sensing composition MEDICAL INDICATORS (a limited partnership under US law) (US) 1988-03-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 IDO1 2586/4885PAM 3233/4885MMP1 1985/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB IDO1 1908/4885PAM 2007/4885MMP1 3028/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC IDO1 3595/4885PAM 4006/4885MMP1 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.